Minichromosome maintenance complex component 6 (MCM6) is involved in initiating DNA replication and is upregulated during licensed G0 phase of the cell cycle. This early expression permits its labeling of more proliferating cells than those by Ki-67. Here using a cohort of 89 endometrioid adenocarcinoma, we report findings made on the prognostic value of MCM6 based on immunohistochemical labeling index (LI) of the protein in comparison with that of Ki67 as no such information is currently available. Additionally, we examined the prognostic values of these markers based on their mRNA expression using a cohort of uterine corpus endometrial carcinoma (UCEC, n = 307) taken from The Cancer Genome Atlas (TCGA) database. Our evidence indicated the presence of a positive correlation between the LI of MCM6 and the histological grade of endometrioid endometrial adenocarcinoma (grade I, 66.7%; grade II, 75.3%; grade III, 81.4%; p < 0.001) and an inverse correlation between the LI of MCM6 and the overall and progression-free survival (p = 0.02 for both). The LI of Ki-67 correlated with grade (p < 0.001), but not survival. The MCM6 and Ki-67 inter-observer intra-class correlation coefficients were excellent: 0.84 (95% confidence interval, 0.83-0.91) and 0.84 (0.77-0.90), respectively. For in silico analyses of the TCGA cohort, both univariate and multivariate Cox analyses (p = 0.003 and p = 0.03, respectively) revealed high MCM6 mRNA Z-scores associated with reduced overall survival. This association was absent for Ki-67. MCM6 is thus a highly reproducible marker of poor prognosis in endometrial cancer. Evaluation of MCM6 should thus be considered in daily practice for risk stratification.
Introduction
Endometrial cancer is the one of the most common gynecological cancers. It ranks fourth among the most frequent cancers in women, after breast, colorectal, and lung cancers.1 In France, in 2012, the recorded number of new cases was 6852, and that of death was 2148. Its incidence has been increasing during the last 15 years.2 Most of these cancers are diagnosed after menopause at a mean age of 62.7 years. The 5-year overall survival rate is around 80%; however, studies predict that two thirds of the advanced stage patients will die.3 , 4 New markers are thus required to improve the risk assessment for these patients. Currently, histological grade and degree of myometrial invasion (included also in the FIGO (International Federation of Gynecology and Obstetrics) staging5) are the only pathological criteria used to predict the prognosis and to determine the therapeutic strategy. Tumor proliferation markers, including Ki-67, are not routinely used in endometrial cancer as previous studies failed to demonstrate their reliabilities as prognostic markers associated with either tumor progression or survival.6
The most frequent mutations associated with these cancers include TP53. Interestingly, loss of expression of certain genes like MSH6 and PMS2 appears to increase the lifetime risk to endometrial cancers. Recent genomic features of endometrial carcinomas permit a classification into four categories: POLE ultramutated, microsatellite instability hypermutated, copy number low, and copy number high alterations that may impact adjuvant treatment.
MCM (minichromosome maintenance) family proteins are highly conserved hexameric complex of DNA-binding proteins. 10 MCMs initiate DNA replication once during the cell cycle and represent a convergence between the multiple signaling pathways involved in cell growth.10 -12 Unlike Ki-67, they are expressed prior to G1 phase of the cell cycle; consequently, anti-MCM antibodies label more cells than anti-Ki-67 antibodies. 12 In lung carcinoma and meningioma, the immunohistochemical labeling index (LI) of minichromosome maintenance complex component 6 (MCM6) correlates positively with histological grade/ subtype and inversely with survival. 13 , 14 In endometrial cancer, the prognostic value of MCM6 has not yet been evaluated; however, two studies reported the prognostic value of other MCM complexes. 15 , 16 In the study by Li et al., MCM7 expression correlated positively with histological grade and was inversely related to survival. In Kato et al., the expressions of MCM2 and MCM3 correlated highly with cell proliferation in normal and hyperplasic tissues; however, in cancer tissues, the expression was weaker and less strongly linked to proliferation. 17 The reproducibility of these markers, notably MCM6, was not evaluated in either study.
The purpose of this study was to compare the prognostic value and the reproducibility of MCM6 vs. Ki-67 in endometrial carcinoma. To do so, we correlated their expressions with the corresponding clinicopathological and survival data using a series of endometrioid endometrial adenocarcinoma from our local biobank (see BMaterials and methods^). In parallel, we performed in silico analyses in a series of uterine corpus endometrial carcinoma (UCEC) taken from TCGA (The Cancer Genome Atlas) to determine possible correlation between the mRNA levels of these two markers and the clinical parameters. Finally, we investigated in the TCGA cohort the functional pathways associated with MCM6 upregulation.
Materials and methods

Population, clinical data, and tissues
Ninety patients were needed-ten in cases group (deaths) and 80 in control group (alive)-to reach 80% statistical power, with an alpha risk of 5%. These 90 patients were included between the 6th of January 2000 and the 12th of June 2008 in the local clinico-biological tissue bank and retrieved from the files of the Department of Pathology (CHRU, Nancy, France); one case was reclassified into mucinous adenocarcinoma and was thus excluded, resulting in the inclusion of 89 consecutive cases (Table 1) . 18 Thirty-eight non-malignant endometrial samples were also retrieved, including normal endometrial tissues in proliferation phase (n = 5) and in secretory phase (n = 7), and cases of non-atypical (n = 13) and atypical (n = 13) hyperplasia.
The histological diagnosis was checked by a microscope. For the cancer samples under consideration, their histological subtypes and grades based on the criteria of WHO (World Health Organization) classification, myometrial invasion, lymphovascular space, and local and nodal invasions were reviewed by two experienced pathologists. A representative formalin-fixed paraffinembedded tissue block was selected for each case.
The main clinical data were collected retrospectively from the Department of Gynecological Surgery (CHRU de Nancy, France) and the Department of Radiotherapy (Institut de Cancérologie de Lorraine, France 
Ethics
The experiments reported here were carried out according to the principles of the Declaration of Helsinki and in agreement with the French laws on biomedical research (institutional review board number DC2008-459; CNIL declaration number 1209171).
Immunohistochemistry
Paraffin sections (5 μm) were immersed in a 10-mM sodium citrate buffer (pH 6) for 20 min at 97°C for dewaxing and antigen retrieval. Staining for MCM6 and Ki-67 was achieved using primary anti-MCM6 (1/400; goat polyclonal, Santa Cruz Biotechnology, Heidelberg, Germany) and anti-Ki-67 (1/200; mouse monoclonal, MIB-1, Dako Cytomation, Glostrup, Denmark) antibodies. Immunohistochemistry was performed with Dako Autostainer Plus (Dako) and a Flex + Envision revelation system (Dako). Negative and positive controls were used throughout the experiment. The LIs of MCM6 and Ki-67 were defined by the percentage of cells showing nuclear expression, counting 500 cells in hot spots.13 Clear nuclear marking independent of its intensity was considered sufficient and positive. Scorings were performed independently by two observers (J.H. and M.A.) blinded to the condition and clinical data. Mean values were then calculated. The two observers re-evaluated samples with large discrepancies in ratings (≥ 20%); mean values were taken after re-ratings. Reproducibility calculations were performed based on the initial ratings of all samples. Staining for p53, MSH6, and PMS2 was evaluated with the following primary antibodies: p53 (1/60; mouse monoclonal, DO7, Novocastra, Newcastle, UK), MSH6 (ready-to-use; rabbit monoclonal, EP49, Dako Cytomation, Glostrup, Denmark), and PMS2 (ready-to-use; rabbit monoclonal, EP51, Dako Cytomation). A tumor was scored positive for p53, when the nuclear labeling was moderate to strong in more than 80% of tumor cells21 , 22; total loss of p53 staining was also rated as present or absent. The expression of MSH6 and PMS2 was considered lost if their nuclear staining in tumor cells was completely absent under the presence of internal positive controls i n normal endometrium, stromal cells, or lymphocytes.23
, 24
Analyses of TCGA data
Data from TCGA UCEC cohort, initially published in Nature, were retrieved using cBioPortal.25 These included clinical information, main molecular features, mRNA Z-scores (RNASeqV2) of both MCM6 and MKI67 (Ki-67), and molecular subgroups (n = 373). 25 The correlations of Z-score with clinicopathological data were analyzed in 307 cases of endometrioid adenocarcinomas for both MCM6 and Ki67 after excluding serous and clear cell subtypes. In cases with MCM6 mRNA Zscores greater than 1 (cBioPortal), the significantly enriched mRNAs in these cases were selected (cBioPortal enrichment tool25) for further analyses of their relevant functional pathways using Gene Ontology (GO) database.26
Statistical analysis
Wilcoxon (two modalities) and Kruskal-Wallis tests (more than two modalities) with Dunn's post-test analysis were used for quantitative variables. A p value of 0.05 was accepted as significant. Correlation between markers was evaluated by Spearman score. To test the reliability of nuclear scoring between the two examiners, the intra-class correlation coefficient (ICC) was 
Results
Population characteristics
The clinical and histological characteristics of the cases of endometrial adenocarcinoma studied are shown in 
MCM6 and Ki-67 protein expressions in endometrial adenocarcinoma
The LI of MCM6 and Ki-67 in the endometrial endometrioid tumors retrieved were analyzed as described in BMaterials and methods.^The distribution of MCM6-and Ki-67-positive cells was relatively heterogeneous, but no relation with any microscopic feature was found, and no significant difference was noticed between the surface and myometrial invasive components. As mentioned in BMaterials and methods,^cell counting was performed in the region of the tissue identified to have the greatest nuclear-labeled cell density. The results are detailed in Table 2 We also performed immunohistochemistry for p53, MSH6, and PMS2. P53 was overexpressed in 10.7% of the cases (9/84). No case showed total negativity for p53. A loss of MSH6 and PMS2 expression was found in 8% (7/88) and 15.9% (14/88) of the cases, respectively. Interestingly, MCM6 LI (p = 0.003) was significantly higher in p53-positive tumors, but no such association for Ki-67 LI (p = 0.23) (Supplementary Fig. S1 ). MCM6 LI correlated also significantly with a loss of MSH6 and/or PMS2 (p = 0.03), but again no such association was found for Ki-67 (p = 0.41) (Supplementary Fig. S2 ).
Survival analyses
Vaginal extension, myometrial invasion, and FIGO tumor stage all correlated significantly with overall survival (OS, p < 0.001; log-rank tests). The presence of metastases was also a significant marker of poor prognosis (OS, p < 0.001; log-rank). Histological grade was correlated neither with OS (log-rank test, p = 0.1; logrank) nor with progression-free survival (PFS) (p = 0.5; log-rank).
Using log-rank test, higher MCM6 LI correlated significantly with shorter OS (p = 0.02) and PFS (p = 0.02) (threshold, LI = 73%, median). Using univariate Cox model analysis, for cases with MCM6 LI above the median (73%), it correlated also significantly with OS (hazard ratio (HR) = 4.8 [CI95%, 1.1-22.8], p = 0.04) and showed a borderline significance for PFS (HR = 8.0 [CI95%, 1-65], p = 0.05). In multivariate Cox regression analysis, in a model combining grade and stage, MCM6 LI did not remain significantly associated with OS (p = 0.14). In contrast, Ki-67 LI was correlated neither with OS (log-rank test, p = 0.79) nor with PFS (log-rank test, p = 0.74) (Fig. 2) .
Correlation between markers
The Spearman test showed a strong correlation between MCM6 and Ki-67, with a rho coefficient measured at 0.55 (p < 0.001) (Supplementary Fig. S3 ). 
Interobserver reproducibility
Benign endometrium
In benign endometrial tissues, we found significantly higher LIs during proliferative phase compared to secretory phase, for Ki-67 (41 vs. 6%, p = 0.002) and MCM6 (93 vs. 57%, p = 0.001). However, between atypical and non-atypical hyperplasia, the LIs of Ki-67 and MCM6 showed no significant difference (Ki-67, 15 Upon further analyses of the 307 cases, we identified a positive correlation between the mRNA level of both MCM6 and Ki-67 and the tumor grade (Kruskal-Wallis test, p < 0.001 for both). In addition, using Cox model, we found an association between high MCM6 mRNA Z-scores and shorter OS (p = 0.003), but not PFS (p = 0.2). Equally, with log-rank test, we unveiled an inverse correlation between MCM6 mRNA level above the 75th percentile and OS (logrank test, p = 0.04), but not with PFS (log-rank test, p = 0.14) (Supplementary Fig. S4 ). Interestingly, Ki-67 mRNA Z-score correlated neither with OS (p = 0.2) nor with PFS (p = 0.46) (univariate Cox model). Regarding the 4 molecular subgroups defined in UCEC TCGA database, MCM6 and Ki-67 mRNA were significantly less expressed in the low copy-number alterations subgroup (p < 0.001). There were no differences between the other subgroups (p = 1) (Supplementary Fig. S5 ). 25 Within the low copy-number alteration subgroup, we did not find any significant correlation between MCM6 mRNA expression and OS (log-rank test, p = 0.68; Cox model, p = 0.43) or PFS (log-rank test, p = 0.47; Cox model, p = 0.86). We examined further the functional annotations of the genes co-expressed with either MCM6 or Ki-67. In cases with MCM6 Z-score greater than 1, 1783 genes were found upregulated and 2375 downregulated. The most significant functional annotations of the upregulated genes associating with MCM6 overexpression included DNA strand elongation involved in DNA replication (p = 8.72e-7), protein localization to chromosome centromeric region (p = 9.76e-5), telomere maintenance via recombination (p = 2.19e-7), CENP-A containing chromatin organization (p = 2.48e-9), tRNA export from nucleus (p = 2.19e-10), mitotic chromosome condensation (p = 4.4e-3), and DNA replication initiation (p = 8.94e-11) (fold enrichment > 8 for all) ( Table 3) . Functional annotations of the downregulated genes included regulation of cytosolic calcium ion concentration (p = 2.3e-2), extracellular matrix organization (p = 7.41e-3), Gprotein-coupled receptor signaling pathway (p = 1.48e-18), cell-cell adhesion (p = 1.1e-3), and inflammatory response (p = 9.85e-3) ( Table 3) .
Discussion
Clinico-pathological prognostic factors in endometrioid type endometrial neoplasm Endometrioid-type endometrial adenocarcinoma, the most frequent histological type, has good prognosis since a large majority can be diagnosed at an early stage.31 Five-year survival rate is about 80% for stage I, but decreases to 30% for stage III and 10% for stage IV.32 The main prognostic factors are age, operability, histological grade, histological type, degree of myometrial invasion, presence of lymphovascular space invasion, and lymph node invasion.33 To date, no additional prognostic marker was validated in these tumors.
Significance of MCM6 LI expression vs. Ki-67 LI expression
Ki-67 is a proliferation marker whose prognostic value in endometrial cancer remains unclear. In several studies, a significant association between Ki-67 LI and histological criteria of malignancy and survival was reported,6 -8 whereas in another no significant correlation was found.9 In our study here, Ki-67 correlates indeed with histological grade, but shows no significant correlation with survival. Given the fact that the inter-observer reproducibility is generally good for Ki-67, the variability reported by different groups34 may stem from technical problems like variations in fixation time and antigen-unmasking procedure, but it may also be caused by the relatively low labeling index. As Ki-67 is upregulated in late G1 phase, anti-Ki-67 antibody does not label all proliferating cells, particularly those exiting quiescent G0 for entry into early G1 phase. 35 Given that maximum Ki-67-labeled regions in tumor slices may be difficult to locate, differentiating cases of good from those of poor prognosis based on only few percentage of differences in Ki-67 LI can be a challenging task. This could probably explain the difficulties encountered in using Ki-67 for prognostic purpose in uterine tumors in clinical practice.
MCM, as part of the replicative complex, plays a critical role in initiation of DNA replication.12 The proliferative index evaluated with anti-MCM6 antibodies correlates highly with that obtained via anti-Ki-67. However, MCM6 is superior marker in that much higher LI can be achieved.36 , 37 Indeed, MCM6 is expressed in the cell cycle much earlier38 , 39 than Ki-67. A couple of studies have analyzed other markers of the MCM complex such as MCM2, MCM3, and MCM7 in endometrial cancers. Li et al. demonstrated a positive correlation between MCM7 expression and histological grade, and an inverse correlation with survival. They also compared MCM7 with Ki-67 and concluded that MCM7 was superior.16 MCM2 and MCM3, studied by Kato et al., correlated significantly with Ki-67 in normal and hyperplastic tissue, but to a lesser degree, in the cases of endometrial cancer. Paradoxically, these two markers were found expressed at higher level in endometrium during endometrial proliferative phase than in tumor tissue, suggesting the existence of abnormalities in the replication system in endometrial adenocarcinomas. 15 To the best of our knowledge, our study here represents the first evaluation on the expression of MCM6 in endometrial cancer. We found strong correlations 50 In the cohort studied here, we indeed found a positive correlation between MCM6 overexpression and MMR protein deficiency (p = 0.03).
Finally, our analyses on the UCEC cohort of TCGA also support the positive correlation between MCM6 expression and tumors with worse prognostic molecular features. Indeed, MCM6 level was higher in POLE, MSI, and high level of copy-number alteration groups than in the low copy number alteration molecular group.25 Our analyses of the TCGA cohort revealed also that tumors with MCM6 overexpression have significant enrichments of mRNAs with functions like DNA replication and elongation, centromere, and mitotic process, supporting thus the roles of MCM6 in cell cycle. Interestingly, the MCM6-enriched tumors expressed significantly less gene functions in matrix organization, cell adhesion, and immune response. Mechanistic studies are needed to understand these original results. 26 
Clinical perspectives
Our data here support the idea of using the labeling index of proliferation marker MCM6 in addition to the classically used criteria for prognostic determination of endometrioid endometrial carcinoma and for follow-ups on interventions such as surgical and adjuvant therapies. Additionally, as reproducibility is an important factor in the evaluation of a new prognostic marker, we calculated the inter-observer reproducibility of MCM6 by calculating the ICC. Our results indicated that MCM6 is as good as Ki-67 in reproducibility (ICC = 0.84 for both). However, further studies are needed to evaluate the inter-laboratory reproducibility. As MCM6 is a low-cost, easy-to-use, and highly reproducible prognostic marker, it shall be considered as a new prognostic marker for a routine utilization in endometrial endometrioid carcinoma.
Conclusion
This study is the first to assess the prognostic value of MCM6 in endometrial cancer, and the results presented here indicate significant correlations existing between the level of the highly reproducible MCM6 labeling and the tumor grade as well as survival. MCM6, by virtue of its higher expression level, shows comparatively non-ambiguous labeling relative to Ki-67; it thus appears as a good candidate marker for the adoption for routine diagnostic distinction tool and for follow-ups for therapeutic interventions of endometrial adenocarcinoma.
